Table 1 all of the aberrant methylations which have been reported among Iranian cancer patients
Gene | Year | Type | population | sample | Results | study (ET AL) |
|---|---|---|---|---|---|---|
dna repair | ||||||
 MGMT, CDH1 | 2010 | Oral | 57N/76Ta | Tissue | Hyper methylation. | Kordi-Tamandan [30] |
 MGMT, BRCA-1 | 2019 | Breast | 27 MTb 31 BTc | Tissue | Hyper methylation in MT. | Paydar [31] |
 MGMT, p53 | 2009 | Glioblastoma | 50 patients | Tissue | MGMT hyper methylation was correlated with p53 expression. | Shamsara [32] |
 MGMT | 2013 | Colorectal | 40 patients 30 controls | Tissue | Hyper methylation. | Farzanehfar [33] |
 MGMT | 2018 | Colorectal | 70 patients | Serum | Hyper methylation. | Alizadeh Naini [34] |
 hMLH1, CDH1 | 2014 | Gastric | 51 patients | Tissue | Hyper methylations were correlated with stage. | Moghbeli [35] |
cell adhesion | ||||||
 RASSF6, RASSF10 | 2017 | Lymphoblastic leukemia | 45 patients | Blood | Hyper methylation. | Younesian [36] |
 HIC1,RASSF1A | 2009 | Breast | 81 patients 100 controls | Tissue | Hyper methylation. | Rasti [37] |
 P16, TSHR, RASSF1A, | 2011 | Thyroid | 25MT 25BT | Tissue | Hyper methylation. | Mohammadi-asl [38] |
 Integrin a4, CDH1 | 2015 | Prostate | 30 patients 40 benign | Tissue | Hyper methylation. | Mostafavi-Pour [39] |
 CDH1 | 2016 | Breast | 98T/10N | Tissue | Hyper methylation. | Naghitorabi [40] |
 CDH1 | 2014 | Breast | 50 N/T | Tissue | Hyper methylation. | Shargh [41] |
 SPG20 | 2017 | Colorectal | 32 N/T | Serum | Hyper methylation. | Rezvani [42] |
cell cycle | ||||||
 P14ARF | 2010 | Oral | 76 patients 57 controls | Tissue | Hyper methylation. | Kordi-Tamandani [43] |
 P16INK4a, p53, p16, MDM2 | 2010 | Esophageal | 50 N/T | Tissue | P16 hyper methylation was correlated with p53 expression. | Taghavi [44] |
 P16 | 2005 | Esophageal | 58 patients 30 controls | Blood | Hyper methylation. | Abbaszadegan [45] |
 P16 | 2018 | Oral | 67 patients 59 controls | Tissue | Hyper methylation was correlated with grade. | Allameh [46] |
 P15INK4a, p16INK4a | 2012 | Oral |  | Tissue | Hyper methylation. | Kordi-Tamandani [47] |
 P16 | 2009 | Breast | 70 patients |  | Hyper methylation. | Vallian [48] |
 P16 | 2008 | Gastric | 52 patients 50 controls | Serum | Hyper methylation. | Abbaszadegan [49] |
 DBC2 | 2012 | Breast | 50 patients 35 controls | Tissue | Hyper methylation. | Hajikhan Mirzaei [50] |
 14-3-3 sigma | 2012 | Breast | 20 patients 20 controls | Tissue | Hyper methylation. | Gheibi [51] |
 UBE2Q1, UBE2Q2 | 2015 | Colorectal | 60 N/T 20 BT | Tissue | UBE2Q2 hypo methylation, UBE2Q1 hyper methylation. | Mokarram [52] |
tyrosine kinases and g protein coupled receptors | ||||||
 VIM, CXCR4, DOK7 | 2018 | Breast | 60 patients 40 controls | Blood | Hypo methylation. | Shirkavand [53] |
 GHSR | 2019 | Gastric | 22 N/T | Tissue | Hyper methylation. | Amini [54] |
 EDNRB | 2017 | Colorectal | 45 N/T | Tissue | Hyper methylation. | Mousavi Ardehaie [55] |
signaling pathways | ||||||
 APC, DDK3, SFRP2, SFRP4, SFRP5, WIF1, WNT5A | 2014 | Colorectal | 125 N/T | Tissue | Aberrant methylations. | Samaei [56] |
 APC | 2009 | Esophageal | 45 N/T | Tissue | Hyper methylation. | Zare [57] |
 SFRP2 | 2016 | Colorectal | 25 patients 25 controls | Fecal | Hyper methylation. | Babaei [58] |
 PTEN, miR-21 | 2016 | Colorectal | 125 N/T | Tissue | MiR-21 over expression, PTEN under expression. | Yazdani [59] |
 PTEN | 2011 | Breast | 53 patients 20 controls | Tissue | Hyper methylation. | Sadeq [60] |
 PTEN | 2016 | Breast | 103 patients 102 controls | Blood | Hyper methylation. | Yari [61] |
developmental factors | ||||||
 ALX4 | 2015 | Colorectal | 25 patients 25 controls | Serum | Hyper methylation. | Salehi [62] |
 PAX5 | 2018 | Gastric | 35 patients 35 controls | Blood | Hyper methylation. | Haghverdi [63] |
 MiR-129-2 | 2019 | Gastric | 50 N/T | Tissue | Hyper methylation. | Alizadeh [64] |
nuclear receptors | ||||||
 ER-a (ER3,4,5) | 2012 | Breast | 60 patients | Tissue | Hyper methylation. | Ramezani [65] |
 ER-a | 2012 | Breast | 100 patients | Tissue | Hyper methylation. | Izadi [66] |
 ER-a | 2012 | Breast | 49 patients 51 controls | Tissue |  | Izadi [67] |
 RARB, p16 | 2011 | Prostate | 42 patients 21 controls | Tissue | Hyper methylation. | Ameri [68] |
apoptosis | ||||||
 APAF1,CASP8 | 2018 | Gastric | 30 patients 30 controls | Blood | Hyper methylation. | Azarkhazin [69] |
 FADD, FAS | 2014 | Oral | 86 patients 68 controls | Tissue | FAS promoter hyper methylation. | Saberi [70] |
 ATM | 2015 | Brain | 30 patients 2 controls | Tissue | Hyper methylation. | Mehdipour [71] |
 CTLA4 | 2014 | Gastric | 85 N/T | Tissue | Hyper methylation. | Kordi-Tamandani [72] |